Despite several extraordinary improvements in cancer immunotherapy, its therapeutic effectiveness against many distinct cancer types remains mostly limited and requires further study. Different microfluidic-based cancer immunotherapy-on-a-chip (ITOC) systems have been developed to help researchers replicate the tumor microenvironment and immune system. Numerous microfluidic platforms can potentially be used to perform various on-chip activities related to early clinical cancer immunotherapy processes, such as improving immune checkpoint blockade therapy, studying immune cell dynamics, evaluating cytotoxicity, and creating vaccines or organoid models from patient samples. In this review, we summarize the most recent advancements in the development of various microfluidic-based ITOC devices for cancer treatment niches and present future perspectives on microfluidic devices for immunotherapy research.
Background: Thrombomodulin (TM), a transmembrane glycoprotein that acts as a plasminogen (Plg) receptor, has been found as a potential molecular and prognostic marker that impacts the spread of various cancers, including malignant melanoma. A previous study showed that TM plays a vital function in angiogenesis activity [1] but its role in the malignant melanoma invasion is unclear. Here, we investigate the role of TM-Plg by using melanoma spheroid (MS) embedded in an extracellular matrix (ECM) modeled to understand how TM-Plg affects the progression of MS invasion. Methods: In this work, A2058 (A2058-GFP and A2058-TMGFP) and MeWo (siC and siTM) MS with different TM expressions were formed, harvested, and embedded in type I collagen gel for invasion assay. TM and Plg expression were determined by western blot. The surface of A2058 MS was observed by SEM imaging. Human Plg, MMPs, and Plg inhibitors, tranexamic acid (TXA) and epsilon-aminocaproic acid (ε-ACA), were utilized to investigate the effect of TM on the plasmin system. Immunofluorescence of TM and F-actin were validated. Results: When the two cell lines expressed with TM, the formed MS invaded to the surrounding matrix more distinctively than that of the TM-silencing ones, with a 2.5-fold difference in the ratio invasive area change. Upon placing the two A2058-TMGFP MS in the vicinity of each other within the ECM, they showed a strong interaction with an observed distance between the two MS from 50 μm to 280 μm. Immunofluorescence of TMGFP assessed the role of TM in MS invasion and interaction in ECM. Microvilli structures were found on the surface of A2058-TMGFP cells that may help the cell have more cellular processes such as adhesion, signal transduction, and metabolic activities. Furthermore, TXA, ε-ACA, and MMP inhibitors inhibited the invasion of A2058-TMGFP MSs in a dose-dependent manner. Human Plg stimulated invasion in TM-expressing MSs while no effect on non-TM MSs. The results suggested that the human Plg only significantly increased the MS invasion with the presence of TM. Conclusion: We concluded that with the presence of TM, the MS invasion and interaction become stronger than MS without TM expression. Moreover, TM enhances MS invasion in the 3D model via interacting Plg. This study provides evidence for the development of TM antagonists in the future to analyze the drug's potential as an anti-metastasis treatment.[1] P. K. Chen et al., “Thrombomodulin functions as a plasminogen receptor to modulate angiogenesis,” FASEB J., vol. 27, no. 11, pp. 4520-4531, 2013, doi: 10.1096/fj.13-227561. Citation Format: Thi Kim Ngan Ngo, Hua-Lin Wu, Cheng-Hsiang Kuo, Ting-Yuan Tu. Effect of thrombomodulin and plasminogen interaction on melanoma spheroid invasion. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 3613.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.